Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Hélène, Kaplon"'
Autor:
Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Lin Wang, Jyothsna Visweswaraiah, Janice M. Reichert
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
ABSTRACTThe ‘Antibodies to Watch’ article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in
Externí odkaz:
https://doaj.org/article/78f76dc3c6894aaab7db6a160a50fdc8
Autor:
Hélène Kaplon, Silvia Crescioli, Alicia Chenoweth, Jyothsna Visweswaraiah, Janice M. Reichert
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTIn this 14th installment of the annual Antibodies to Watch article series, we discuss key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecast events that might occur in 2023. As of mid-November
Externí odkaz:
https://doaj.org/article/2ffd642807bf49b48c679d5a0397d669
Autor:
Priyanka Devi-Marulkar, Solène Fastenackels, Pierre Karapentiantz, Jérémy Goc, Claire Germain, Hélène Kaplon, Samantha Knockaert, Daniel Olive, Marylou Panouillot, Pierre Validire, Diane Damotte, Marco Alifano, Juliette Murris, Sandrine Katsahian, Myriam Lawand, Marie-Caroline Dieu-Nosjean
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-16 (2022)
Regulatory T cells (Tregs) have similar immune profiles in tertiary lymphoid structures of lung cancer and non-TLS areas, with tumor-infiltrating Tregs found to inhibit the proliferation and cytokine secretion of CD4 + conventional T cells.
Externí odkaz:
https://doaj.org/article/6843b8158e4442199fa24d4eee02cf0d
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
In this 13th annual installment of the annual ‘Antibodies to Watch’ article series, we discuss key events in commercial antibody therapeutics development that occurred in 2021 and forecast events that might occur in 2022. Regulatory review of ant
Externí odkaz:
https://doaj.org/article/f959311144474c1381d5a10a4877052e
Autor:
Hélène Kaplon
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with a 5-year relative survival rate of 5%. The desmoplastic stroma found in the tumor microenvironment of PDAC is suggested to be partly responsible for the resistance to most
Externí odkaz:
https://doaj.org/article/1b972d2bb7954bb1bdf9c6c5b8d898b2
Autor:
Hélène Kaplon, Yufei Luo, Frédéric De Ceuninck, Agnès Lalande, Sophie Courtade-Gaiani, Laurence Laigle, Philippe Moingeon
Publikováno v:
Osteoarthritis and Cartilage Open, Vol 3, Iss 4, Pp 100221- (2021)
Objective: Understanding the heterogeneity and pathophysiology of osteoarthritis (OA) is critical to support the development of tailored disease-modifying treatments. To this aim, transcriptomics tools are highly relevant to delineate dysregulated mo
Externí odkaz:
https://doaj.org/article/4cf2075a13b540a8a40b0a21dab2775b
Autor:
Claire Germain, Priyanka Devi-Marulkar, Samantha Knockaert, Jérôme Biton, Hélène Kaplon, Laïla Letaïef, Jérémy Goc, Agathe Seguin-Givelet, Dominique Gossot, Nicolas Girard, Pierre Validire, Marine Lefèvre, Diane Damotte, Marco Alifano, François M. Lemoine, Keith E. Steele, Jean-Luc Teillaud, Scott A. Hammond, Marie-Caroline Dieu-Nosjean
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The presence of tertiary lymphoid structures (TLS) in the tumor microenvironment is associated with better clinical outcome in many cancers. In non-small cell lung cancer (NSCLC), we have previously showed that a high density of B cells within TLS (T
Externí odkaz:
https://doaj.org/article/757b1a291fa64d989f66f304930a5ace
Autor:
Hélène Kaplon, Janice M. Reichert
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The coronavirus disease 2019 (COVID-19) pandemic
Externí odkaz:
https://doaj.org/article/61df18d7eb31477188252f804e174b18
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
This 2020 installment of the annual ‘Antibodies to Watch’ series documents the antibody therapeutics approved in 2019 and in regulatory review in the United States or European Union, as well as those in late-stage clinical studies, as of November
Externí odkaz:
https://doaj.org/article/07402be6d623439e82723964987f8dca
Publikováno v:
médecine/sciences
médecine/sciences, EDP Sciences, 2021, 37 (2), pp.130-133. ⟨10.1051/medsci/2020276⟩
médecine/sciences, 2021, 37 (2), pp.130-133. ⟨10.1051/medsci/2020276⟩
médecine/sciences, EDP Sciences, 2021, 37 (2), pp.130-133. ⟨10.1051/medsci/2020276⟩
médecine/sciences, 2021, 37 (2), pp.130-133. ⟨10.1051/medsci/2020276⟩
International audience